ADCT_4C_TM.png
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
06 nov. 2023 07h00 HE | ADC Therapeutics SA
LAUSANNE, Switzerland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the...
22157.jpg
Global CD19 Antibody Market Set to Surpass $10 Billion by 2028: A Revolutionary Era in Immunotherapy
03 nov. 2023 07h43 HE | Research and Markets
Dublin, Nov. 03, 2023 (GLOBE NEWSWIRE) -- The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The global CD19 Antibody...
ADCT_4C_TM.png
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
02 nov. 2023 10h10 HE | ADC Therapeutics SA
Presentations to highlight clinical utility of ZYNLONTA® (loncastuximab tesirine-lpyl) as a single agent and in combination Oral presentation to include initial results of investigator-initiated...
22157.jpg
Global Antibody Drug Conjugates Market Poised to Reach $19.8 Billion by 2028, Fueled by Increasing Cancer Prevalence and Clinical Advancements
26 oct. 2023 07h33 HE | Research and Markets
Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type...
ADCT_4C_TM.png
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
24 oct. 2023 07h00 HE | ADC Therapeutics SA
LAUSANNE, Switzerland, Oct. 24, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, November 7, 2023 at 8:30...
ADCT_4C_TM.png
ADC Therapeutics to Participate in September Investor Conferences
05 sept. 2023 07h00 HE | ADC Therapeutics SA
LAUSANNE, Switzerland, Sept. 05, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in two investor conferences in...
Antibody Drug Conjugate Market
Antibody Drug Conjugate (ADC) Markets, 2035
24 août 2023 06h33 HE | Research and Markets
Dublin, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key...
22157.jpg
Global Antibody Drug Conjugate (ADC) Forecast to 2028 - Next-Generation ADCs Spurring Growth Opportunities
22 août 2023 08h03 HE | Research and Markets
Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The report...
ADCT_4C_TM.png
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
08 août 2023 07h00 HE | ADC Therapeutics SA
2Q 2023 ZYNLONTA®1 net sales increased 11% year-over-year; Implemented new go-to-market strategy during the quarter to support growth Operating expenses decreased 20%2 year-over-year due to portfolio...
ADCT_4C_TM.png
ADC Therapeutics veranstaltet am 8. August 2023 eine Telefonkonferenz zu den Finanzergebnissen des zweiten Quartals 2023
01 août 2023 07h00 HE | ADC Therapeutics SA
LAUSANNE, Schweiz, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) gab heute bekannt, dass es am Dienstag, den 8. August 2023, um 8:30 Uhr EDT eine Telefonkonferenz und einen...